The American Journal of Surgery
Volume 200, Issue 3 , Pages 374-377 , September 2010

Diminishing morbidity with the increased use of sentinel node biopsy in breast carcinoma

  • Andrea Bafford, M.D.

      Affiliations

    • Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    • ,
  • Michele Gadd, M.D.

      Affiliations

    • Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
    • ,
  • Xiangmei Gu, M.S.

      Affiliations

    • Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    • ,
  • Stuart Lipsitz, Sc.D.

      Affiliations

    • Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    • ,
  • Mehra Golshan, M.D.

      Affiliations

    • Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Tel.: 617-632-2174; fax: 617-582-7740

Received 30 April 2009 ,Revised 21 October 2009

References 

  1. Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer. 1998;83:1362–1368
  2. Roses DF, Brooks AD, Harris MN, et al. Complications of level I and II axillary dissection in the treatment o carcinoma of the breast. Ann Surg. 1999;230:194–201
  3. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  4. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–401
  5. Krag DN, Harlow S, Weaver D, et al. Radiolabeled sentinel node biopsy: collaborative trial with the National Cancer Institute. World J Surg. 2001;25:823–828
  6. Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery. Ann Surg. 2007;245:452–461
  7. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553
  8. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312–4321
  9. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599–609
  10. Crane-Okada R, Wascher RA, Elashoff D, et al. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol. 2008;15:1996–2005
  11. Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the setinella-GIVOM Italian randomized clinical trial. EJSO. 2007;34:508–513
  12. Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000;88:608–614
  13. Sclafani LM, Baron RH. Sentinel lymph node biopsy and axillary dissection: added morbidity of the arm, shoulder and chest wall after mastectomy and reconstruction. Cancer J. 2008;14:216–222
  14. Gill G SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? (One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial). Ann Surg Oncol. 2009;16:266–275
  15. Olson JA, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group trials Z0010 and Z0011. J Clin Oncol. 2008;26:3530–3535
  16. Goyal A, Newcombe RG, Chhabra A, et al. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND. Ann Surg Oncol. 2008;15:262–267
  17. Krag DN, Stewart JA, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–888
  18. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–2566
  19. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500

PII: S0002-9610(10)00054-1

doi: 10.1016/j.amjsurg.2009.10.012

The American Journal of Surgery
Volume 200, Issue 3 , Pages 374-377 , September 2010

Article Tools

* Image Usage & Resolution